Contains Nonbinding Recommendations
Draft – Not for Implementation

Heparin-Containing Medical Devices and Combination Products: Recommendations for Labeling and Safety Testing

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Document issued on: July 9, 2015

You should submit comments and suggestions regarding this draft document within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov. Identify all comments with the docket number listed in the notice of availability that publishes in the Federal Register.

For questions regarding medical products regulated by the Center for Devices and Radiological Health (CDRH), contact Angela Krueger at 301-796-6380 or by electronic mail at angela.krueger@fda.hhs.gov.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Office of Device Evaluation
Additional Copies

Additional copies are available from the Internet. You may also send an e-mail request to CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please use the document number (1817) to identify the guidance you are requesting.
Heparin-Containing Medical Devices and Combination Products: Recommendations for Labeling and Safety Testing

Draft Guidance for Industry and Food and Drug Administration Staff

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

1. Introduction

The United States Pharmacopeia (USP)\(^1\) drug substance monograph for Heparin Sodium, and drug product monographs for Heparin Lock Flush Solution and Heparin Sodium Injection, recently have undergone several revisions following serious and fatal events related to the use of heparin sodium products.\(^2\) Investigation of heparin product overdose errors identified the expression of drug strength in the labels as a major contributing factor in these errors. When finalized, this guidance document will address these safety concerns by clarifying new expectations for labeling with regard to the revised heparin USP monographs,\(^3\) as well as outline safety testing recommendations.

In addition, the outbreak of serious and often fatal events due to heparin contamination with oversulfated chondroitin sulfate (OSCS) in 2008 led the USP to include in its drug substance monograph additional testing of heparin sodium to ensure its quality and purity. When finalized, this guidance will also outline use of conformance to the monographs in premarket submissions,

---


\(^2\)USP37–NF32, at 3222 (Heparin Sodium); USP37–NF32, at 3227 (Heparin Sodium Injection); and at 3228 (Heparin Lock Flush Solution). The FD&C Act requires a drug product to conform with the related official USP drug product monograph. Sections 501(b) and 502(g) of the FD&C Act.

\(^3\)See also FDA Drug Safety Communication: Important change to heparin container labels to clearly state the total drug strength at [http://www.fda.gov/Drugs/DrugSafety/ucm330695.htm](http://www.fda.gov/Drugs/DrugSafety/ucm330695.htm).
specifically testing and documentation requirements and/or recommendations contained in the current USP monographs and the guidance document *Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality* (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291390.pdf).\(^4\)

Note that recommendations made in this guidance reflect FDA’s current position on this issue and may change in the future as new scientific information or new detection methods become available. FDA intends to revise this draft guidance document as needed to reflect any additional revisions to these USP heparin monographs.

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

2. Scope

This guidance provides labeling and safety testing recommendations for medical devices and for combination products with a device primary mode of action that include heparin sodium or low molecular weight heparin and assigned to CDRH for regulation.\(^5\) Products that include only bonded coatings of heparin sodium or low molecular weight heparins with a fixed total dose of heparin are unlikely to pose a risk of heparin overdose; however, these devices should also comply with the recommendations in this guidance.

3. Background

Heparin has been identified as a high-alert medication by the Institute for Safe Medication Practices (ISMP) due to a heightened risk of patient harm when dosed incorrectly. In 2003, the USP’s Safe Medication Use Expert Committee recognized a recurring trend of medication errors related to misinterpretation of the expression of concentration on the labeling of injectable products, resulting in serious consequences to patients, including death. Heparin products span a wide range of doses and concentrations based on the indication for use for the product as well as the intended patient population. Heparin administration for systemic anticoagulation is provided as final concentrations ranging from 50-100 units/mL. The source vials from which these dilutions are prepared contain concentrations ranging from 1,000-20,000 units/mL. When heparin sodium is only intended to maintain patency of an indwelling intravascular catheter, the

---

\(^4\) The Agency updates guidances periodically. To make sure you have the most recent version of this guidance, check the CDER guidance page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.

\(^5\) Some devices for in vitro diagnostic uses include heparin. Products that include a device and heparin for in vivo use are combination products. Center assignment for combination products is based on which constituent part (the drug or device in this case) provides the primary mode of action (PMOA), i.e., makes the greatest contribution to the overall intended therapeutic effects of the combination product. See 21 CFR 3.2. Combination products that include heparin and a device are assigned to CDRH if the device provides the PMOA.
heparin lock flush solution (which is regulated by FDA as a drug-device combination product with a device primary mode of action (see 71 FR 47499, August 17, 2006)), typically includes heparin concentrations ranging from 1-100 units/mL packaged in 1-30 mL vials with total drug content ranging from 1 unit to 1,000 units or a variety of fill volumes in prefilled syringes with total drug amounts per syringe ranging from 1 unit to 500 units.

In 2007, the USP Parenteral Products-Industrial Expert Committee recommended revisions to the new "Strength and Total Volume for Single- and Multiple-Dose Injectable Drug Products" section of USP General Chapter <1> Injections. These revisions became official in 2009. This chapter directs that the strength per total volume should be the primary and prominent expression on the principal display panel of the label, followed in close proximity by strength per mL enclosed by parentheses. Following these changes, FDA and ISMP expressed concern that the labeling prescribed in the Heparin Lock Flush Solution monograph (and in the Heparin Sodium Injection monograph) does not conform with the requirements in General Chapter <1> Injections. USP's Expert Committees, including the committee responsible for these Heparin monographs, Monographs-Biologies and Biotechnology 1, proposed revisions to the labeling sections of the heparin monographs that will require the product container labels to comply with the USP standards for injectable medications, specifically, General Chapter <1> Injections. Those revisions became official May 1, 2013.

4. Labeling Statements

A. For Heparin Lock Flush Solution Products

The USP monograph for Heparin Lock Flush Solution requires the product labels express strength per total container volume as the primary expression of strength, followed in close proximity by strength per mL enclosed by parentheses, for single- and multiple-dose injectable drug products. The strength per total volume should be the primary and prominent expression of the principal display panel of the label. For example:

- Total strength/total volume: 100 USP Units /10 mL
- Strength/mL: (10 USP Units /mL)

For products containing a volume of less than 1 mL, the strength per fraction of an mL should be the only expression of strength. For example;

---

6 USP has announced plans to relocate this information to General Chapter <7> Labeling in the near future (http://www.gphaonline.org/media/cms/Donna_Bohannon.pdf).

7 Under section 201(m) of the FD&C Act, labeling means all labels and other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article. Under section 201(k) of the FD&C Act, “The term ‘label’ means a display of written, printed, or graphic matter upon the immediate container of any article; and a requirement made by or under authority of this Act that any word, statement, or other information appear on the label shall not be considered to be complied with unless such word, statement, or other information also appears on the outside container or wrapper, if any there be, of the retail package of such article, or is easily legible through the outside container or wrapper.

8 USP37–NF32, at 3228 (Heparin Lock Flush Solution).

9 Id.
Strength/mL: 100 USP Units /0.5 mL

The Agency further recommends that the above information be included in the instructions for use as part of the device/combination product description. Consistent with the monograph, the label must identify the organ (e.g., intestinal mucosa) and the animal species (e.g., porcine) from which the heparin sodium is derived.10

B. For Heparin-Bonded Products

For heparin-bonded products, the total amount of heparin per total surface area should be displayed on the primary package label followed by the concentration per area unit in parentheses. For example:

Total amount of heparin/total surface area: 100 USP Units /total surface area2
Strength/area unit: (10 USP Units)/unit of surface area2

The Agency further recommends that the above information be included in the instructions for use as part of the device/combination product description, and that the labeling identify the tissue (e.g., intestinal mucosa) and the animal species (e.g., porcine) from which the heparin sodium is derived.

5. Safety Testing for Heparin-Containing Products

Manufacturers of Heparin Lock Flush Solution must comply with the current USP monograph for that product, as well as the USP drug substance monograph for Heparin Sodium. Manufacturers of Heparin Sodium Injection must comply with the current USP monograph for that product, as well as the USP drug substance monograph for Heparin Sodium. See sections 501(b) and 502(g) of the FD&C Act. Firms are also recommended to follow the guidance document, *Heparin for Drug and Medical Device use: Monitoring Crude Heparin for Quality*, mentioned above.11 In addition, we recommend that manufacturers who receive heparin sodium drug substance or active pharmaceutical ingredient (API) that is represented to be “USP” to produce a combination product or an in vitro diagnostic medical device that includes heparin sodium or low molecular weight heparin ensure and document that the heparin has been tested according to the current USP drug substance monograph, and that it is manufactured and/or tested consistent with applicable guidance documents on heparin. Manufacturers of medical devices and combination products which include heparin must comply with the elements of safety testing that are required to be performed and documented as part of compliance with the Quality System (QS) regulation for devices, and with both the QS regulation and current good manufacturing requirements for drugs if the product is a combination product (see 21 CFR Part 4).

10 Id.
11 In addition, the Center for Drug Evaluation and Research (CDER) has issued a draft guidance for industry, *Immunogenicity-Related Considerations for the Approval of Low Molecular Weight Heparin for NDAs and ANDAs*, available at http://www.fda.gov/downloads/drugs/guidanceregressive/ucm392194.pdf. When final, this guidance will represent the agency’s current thinking on this topic.
Premarket submissions to CDRH – premarket notification (510(k)) submissions, premarket approval (PMA) applications, de novo requests, and humanitarian device exemption (HDE) applications – should describe the heparin product in detail and document compliance with heparin safety testing. Please note, however, that heparin testing data and records should be maintained on file with the medical device or combination product manufacturer, but do not need to be included in premarket submissions. See Appendix A for more details. The premarket submission should include the following information:

- Heparin source-tissue and species (e.g., porcine intestinal mucosa);
- Confirmation of the species origin of heparin sodium (e.g., porcine);
- Identification of the actual manufacturer (i.e. name, address and contact information) of the heparin sodium API and any repackers and distributors who handle the heparin sodium before receipt.

The premarket submission should also provide the following to indicate the manufacturer’s conformance with testing parameters from the guidance Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291390.pdf):

- Testing for OSCS using methods that are qualified and suitable for detecting low levels of OSCS concentrations (e.g., strong anion exchange high-pressure liquid chromatography and $^1$H Nuclear Magnetic Resonance).
- Heparin-containing combination products and medical devices should also comply with the contaminant safety testing recommendations in the USP monograph on Heparin Sodium and CDER’s guidance recommendations to detect OSCS contamination of heparin and for identification of the animal origin of the heparin.
Appendix A - Documentation of Heparin Safety Testing

FDA recommends that the following Heparin Safety Controls testing data and records of crude heparin, heparin API, and heparin product be maintained on file:

- **Heparin Crude:**
  
  - Procedure(s) followed to reject, control, and properly dispose of any crude heparin found to contain any amount of OSCS or ruminant material contaminant and notify the local FDA district office of the finding, as well as documentation of all related actions taken.

- **Heparin Sodium (including Heparin Sodium used to make Low Molecular Weight Heparin):**
  
  - Description of controls used to prevent the use of heparin containing OSCS or any other contaminants (e.g., USP monograph tests, ICH Q7, *Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7*).


  - Although batches of Heparin Sodium that have deviated, failed or contaminated should be rejected and not enter the supply chain, all procedure(s) followed to fully and promptly investigate and resolve deviations and failure of quality or document that the Heparin Sodium has been in compliance, as well as documentation of all related actions taken should be maintained on file.

- **Heparin Product:**
  
  - If further manipulation of the USP heparin product in your manufacturing activities is required, documentation that this additional manipulation will not interfere with product purity or effectiveness.